News & Updates

Show Multimedia Only

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

13 hours ago

Extended-release nalbuphine quells IPF-related cough

01 Feb 2026 by

The investigational extended-release nalbuphine helps alleviate chronic cough associated with idiopathic pulmonary fibrosis (IPF), as shown in the phase IIb CORAL study.

Extended-release nalbuphine quells IPF-related cough

01 Feb 2026

Advanced maternal age linked to reduced risk of allergic diseases in early childhood

30 Jan 2026

Children born to older mothers appear to have a reduced likelihood of food allergy, wheezing, and house dust mite sensitization in early childhood, according to a study.

Advanced maternal age linked to reduced risk of allergic diseases in early childhood

30 Jan 2026

Genetic testing + prevention of anaemia and pre-eclampsia may reduce peripartum cardiomyopathy

30 Jan 2026 by

Early recognition and awareness of signs and symptoms as well as genetic testing for predisposition may reduce the incidence of peripartum cardiomyopathy (PPCM), according to findings of a Hong Kong population-based study.

Genetic testing + prevention of anaemia and pre-eclampsia may reduce peripartum cardiomyopathy

30 Jan 2026

Saline spray clears obstructive sleep-disordered breathing symptoms for some kids

29 Jan 2026 by

Two 6-week courses of intranasal saline help resolve symptoms of obstructive sleep-disordered breathing (OSDB) for about half of the children in the MIST+ trial, with efficacy similar to that of intranasal steroid.

Saline spray clears obstructive sleep-disordered breathing symptoms for some kids

29 Jan 2026

Bisoprolol makes no difference in moderately severe COPD

28 Jan 2026

In the treatment of patients with moderately severe chronic obstructive pulmonary disease (COPD), the use of bisoprolol has no significant effect on overall cardiorespiratory health, all-cause mortality, or serious cardiorespiratory events when compared with placebo, as shown in a phase III study.

Bisoprolol makes no difference in moderately severe COPD

28 Jan 2026

Sotrovimab benefits select hospitalized COVID-19 patients

23 Jan 2026 by

In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.

Sotrovimab benefits select hospitalized COVID-19 patients

23 Jan 2026

Postop use of wearables OK for patients

22 Jan 2026 by

According to a survey, integrating wearables into postoperative care is well-received among hospitalized postop patients, paving the way for their future implementation.

Postop use of wearables OK for patients

22 Jan 2026

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

22 Jan 2026 by

First-line osimertinib plus chemotherapy demonstrated a median overall survival (mOS) of nearly 4 years in patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) in the final OS analysis of the FLAURA 2 trial.

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

22 Jan 2026

Nonadherence to PAH medications compromises outcomes

22 Jan 2026

Patients with pulmonary arterial hypertension (PAH) who do not adhere to medications appear to have poor clinical outcomes, according to a study.

Nonadherence to PAH medications compromises outcomes

22 Jan 2026

News & Updates

Showing Respirology articles

Showing

Specialty:

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

Extended-release nalbuphine quells IPF-related cough

Extended-release nalbuphine quells IPF-related cough

Advanced maternal age linked to reduced risk of allergic diseases in early childhood

Advanced maternal age linked to reduced risk of allergic diseases in early childhood

Genetic testing + prevention of anaemia and pre-eclampsia may reduce peripartum cardiomyopathy

Genetic testing + prevention of anaemia and pre-eclampsia may reduce peripartum cardiomyopathy

Saline spray clears obstructive sleep-disordered breathing symptoms for some kids

Saline spray clears obstructive sleep-disordered breathing symptoms for some kids

Bisoprolol makes no difference in moderately severe COPD

Bisoprolol makes no difference in moderately severe COPD

Sotrovimab benefits select hospitalized COVID-19 patients

Sotrovimab benefits select hospitalized COVID-19 patients

Postop use of wearables OK for patients

Postop use of wearables OK for patients

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

Nonadherence to PAH medications compromises outcomes

Nonadherence to PAH medications compromises outcomes